Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transparency comments through Nov. 6

This article was originally published in The Tan Sheet

Executive Summary

FDA accepts comments on its transparency initiative through Nov. 6, after which the Transparency Task Force will conduct its second public meeting. The agency's transparency Web site, which features a blog about the initiative, will operate while the comment docket is open. The task force consists of Principal Deputy Commissioner Josh Sharfstein, the directors of each of FDA's centers, acting Associate Commissioner for Regulatory Affairs Michael Chappell, acting Chief Counsel Michael Landa and acting Chief Scientist Jesse Goodman. Commissioner Margaret Hamburg appointed the task force to identify how to improve communication and better explain agency decisions (1"The Tan Sheet" June 8, 2009)

You may also be interested in...

Transparency task force to mull announcements of NDAs

FDA will ask whether the public should be informed when sponsors file applications for drugs and other products, at a second public Transparency Task Force meeting Nov. 3 in Washington to discuss the communication issues. Topics include "early communication about emerging safety issues concerning FDA-regulated products," disclosure of information about abandoned or withdrawn product applications and communication of agency decisions about pending product applications. Attendees must register by 5 p.m. on Oct. 27, and comments must be submitted electronically by Nov. 6 (1"The Tan Sheet" Sept. 14, 2009)

Supplement Industry Wants Answers From FDA Transparency Task Force

Supplement industry leaders want FDA's Transparency Task Force to shed light on the agency's decision-making process and explain controversial and ambiguous policies as well as improve communication

Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views

While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts